Skip to Content

Caspofungin Pregnancy and Breastfeeding Warnings

Caspofungin is also known as: Cancidas

Medically reviewed on Aug 15, 2018

Caspofungin Pregnancy Warnings

Caspofungin has been assigned to pregnancy category C by the FDA. Reproduction studies in rats and rabbits demonstrated evidence of embryotoxicity (e.g. incomplete ossification of the skull, torso, and of the talus/calcaneus, increases in resorption, and periimplantation losses) at doses yielding exposures similar to those seen in patients treated with normally recommended dosages. There are no controlled data in human pregnancy. Caspofungin should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Caspofungin Breastfeeding Warnings

There are no data on the excretion of caspofungin into human milk. The manufacturer recommends that caution be used when administering caspofungin to nursing women.

See references

References for pregnancy information

  1. "Product Information. Cancidas (caspofungin)" Merck & Co, Inc, West Point, PA.

References for breastfeeding information

  1. "Product Information. Cancidas (caspofungin)" Merck & Co, Inc, West Point, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide